report claims Novo Nordisk's semaglutide 2 mg dose reduced the risk of serious cardiovascular events by 6%. No study details or confirmation are available.
bullish 65 · impact 40
Novo Nordisk will pay $300 million upfront for global rights to Hengrui's HRS-1596. The deal could be worth up to $2.6 billion with milestones.
Novo Nordisk provides weekly update on share repurchase programme.
bullish 60 · impact 15
Novo Nordisk Series B rises 0.3%, outperforms weaker Nordic market.
bullish 60 · impact 10Novo Nordisk open to direct NYSE listing, CEO tells FT.
neutral 50 · impact 30Deutsche Bank cut its price target on Novo Nordisk to DKK 245 from DKK 265, reflecting a more cautious outlook.
bearish 40 · impact 20
Novo Nordisk's long-term pipeline plan fails to impress investors, lacks near-term targets
bearish 30 · impact 60
Novo Nordisk CEO identifies liver disease and cardiovascular as key expansion areas despite recent setbacks.
neutral 50 · impact 30Novo Nordisk CEO stated 7 million US prescriptions have been written for the Wegovy pill and that the company recently gained meaningful market share. He also committed to strengthening diabetes care.
neutral 50 · impact 10
Novo Nordisk and Anthropic partner on AI-driven drug development
neutral 50 · impact 40
Novo Nordisk is shortening its public brand to simply "Novo." The move comes alongside a company-wide cultural reset as obesity-drug competition heats up.
neutral 50 · impact 35Semaglutide showed no new safety concerns in a pediatric study, supporting its use in children.
bullish 70 · impact 40